Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Louis Pasteur Center For Medical Research has 1 pending office action. This matter is assigned to 1 distinct examiner, BERRY, LAYLA D, who is the busiest examiner for the portfolio. There are 0 distinct art units reported for this activity. This profile indicates a focused point of contact at the patent office, with the entire pending workload concentrated under the assigned examiner.
The busiest examiner's workload of 1 pending action matches the total volume of the portfolio. This high level of concentration suggests that the company's immediate patent prospects are tied to the specific interpretations of the assigned individual. The presence of 0 distinct art units suggests that the matter may be in a preliminary stage, requiring a strategy tailored to the specific feedback received in this case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18719731 | Intestinal Tumor Suppressor, PGE2 Production Inhibitor, and IL-22BP Production Promoter | BERRY, LAYLA D | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18719731 | Intestinal Tumor Suppressor, PGE2 Production Inhibitor, and IL-22BP Production Promoter | BERRY, LAYLA D | — | §102§103 | Non-Final OA | — | Pending | Jun 13, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial